Insider Selling: Pulmonx Co. (NASDAQ:LUNG) CEO Sells 27,689 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) CEO Steven S. Williamson sold 27,689 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the sale, the chief executive officer now owns 194,342 shares of the company's stock, valued at $1,387,601.88. This represents a 12.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulmonx Trading Up 0.5 %

NASDAQ:LUNG traded up $0.04 during trading hours on Friday, hitting $7.48. 245,140 shares of the stock were exchanged, compared to its average volume of 335,956. The company's 50 day moving average is $6.96 and its two-hundred day moving average is $6.94. Pulmonx Co. has a twelve month low of $5.46 and a twelve month high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $297.67 million, a P/E ratio of -5.19 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to analysts' expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, sell-side analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Remove Ads

Analyst Ratings Changes

LUNG has been the topic of several recent research reports. Wells Fargo & Company cut their price target on Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Citigroup restated a "neutral" rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.75.

Institutional Investors Weigh In On Pulmonx

Several hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp bought a new stake in shares of Pulmonx during the fourth quarter worth $372,000. ProShare Advisors LLC bought a new stake in Pulmonx in the 4th quarter worth about $72,000. Millennium Management LLC grew its position in Pulmonx by 26.6% in the 4th quarter. Millennium Management LLC now owns 183,069 shares of the company's stock worth $1,243,000 after purchasing an additional 38,425 shares in the last quarter. Graham Capital Management L.P. boosted its stake in Pulmonx by 73.3% in the fourth quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock valued at $123,000 after acquiring an additional 7,641 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in shares of Pulmonx by 8.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 392,836 shares of the company's stock valued at $2,667,000 after buying an additional 32,049 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.